3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Sell
12
ATNF Quote, Financials, Valuation and Earnings
Last price:
$1.59
Seasonality move
:
2.08%
Day range:
$1.53 - $1.68
52-week range:
$1.16 - $17.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.84x
Volume:
417.1K
Avg. volume:
733.8K
1-year change:
-54.81%
Market cap:
$3.1M
Revenue:
--
EPS (TTM):
-$4.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ATNF
180 Life Sciences
|
-- | -- | -- | -- | -- |
|
IBIO
iBio
|
-- | -$0.45 | -100% | -89.82% | $3.60 |
|
NBY
NovaBay Pharmaceuticals
|
$2.5M | -$0.24 | -60.77% | -99.16% | $7.30 |
|
OGEN
Oragenics
|
-- | -- | -- | -- | -- |
|
PTN
Palatin Technologies
|
-- | -$0.42 | -100% | -25% | -- |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ATNF
180 Life Sciences
|
$1.58 | -- | $3.1M | -- | $0.00 | 0% | -- |
|
IBIO
iBio
|
$2.46 | $3.60 | $22.5M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.64 | $7.30 | $3.1M | -- | $0.00 | 0% | 0.07x |
|
OGEN
Oragenics
|
$0.41 | -- | $5M | -- | $0.00 | 0% | 1.61x |
|
PTN
Palatin Technologies
|
$1.32 | -- | $25.8M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.73 | -- | $4.8M | -- | $0.00 | 0% | 1.59x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ATNF
180 Life Sciences
|
-- | -5.879 | -- | -- |
|
IBIO
iBio
|
4.41% | 8.236 | 5.41% | 3.89x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.365 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | 2.471 | -- | -- |
|
PTN
Palatin Technologies
|
-- | -3.016 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.870 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ATNF
180 Life Sciences
|
-- | -$979.1K | -- | -- | -- | -$223.7K |
|
IBIO
iBio
|
-- | -$4.1M | -90.99% | -148.3% | -1820.57% | -$3.7M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
OGEN
Oragenics
|
-- | -$2.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
$350K | -$7.8M | -- | -- | -2356.3% | -$7M |
|
TOVX
Theriva Biologics
|
-- | -$5M | -- | -- | -- | -$3.9M |
180 Life Sciences vs. Competitors
-
Which has Higher Returns ATNF or IBIO?
iBio has a net margin of -- compared to 180 Life Sciences's net margin of -4444.57%. 180 Life Sciences's return on equity of -- beat iBio's return on equity of -148.3%.
Company Gross Margin Earnings Per Share Invested Capital ATNF180 Life Sciences-- -$0.85 -- IBIOiBio-- -$0.46 $22.3M -
What do Analysts Say About ATNF or IBIO?
180 Life Sciences has a consensus price target of --, signalling upside risk potential of 96102.49%. On the other hand iBio has an analysts' consensus of $3.60 which suggests that it could grow by 46.34%. Given that 180 Life Sciences has higher upside potential than iBio, analysts believe 180 Life Sciences is more attractive than iBio.
Company Buy Ratings Hold Ratings Sell Ratings ATNF180 Life Sciences0 0 0 IBIOiBio1 0 0 -
Is ATNF or IBIO More Risky?
180 Life Sciences has a beta of 0.139, which suggesting that the stock is 86.106% less volatile than S&P 500. In comparison iBio has a beta of -3.266, suggesting its less volatile than the S&P 500 by 426.584%.
-
Which is a Better Dividend Stock ATNF or IBIO?
180 Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 180 Life Sciences pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATNF or IBIO?
180 Life Sciences quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. 180 Life Sciences's net income of -$836.7K is higher than iBio's net income of -$4M. Notably, 180 Life Sciences's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 180 Life Sciences is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATNF180 Life Sciences-- -- -- -$836.7K IBIOiBio-- -- $175K -$4M
-
Which has Higher Returns ATNF or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to 180 Life Sciences's net margin of -49.65%. 180 Life Sciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital ATNF180 Life Sciences-- -$0.85 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About ATNF or NBY?
180 Life Sciences has a consensus price target of --, signalling upside risk potential of 96102.49%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 479.77%. Given that 180 Life Sciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe 180 Life Sciences is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings ATNF180 Life Sciences0 0 0 NBYNovaBay Pharmaceuticals2 0 0 -
Is ATNF or NBY More Risky?
180 Life Sciences has a beta of 0.139, which suggesting that the stock is 86.106% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.
-
Which is a Better Dividend Stock ATNF or NBY?
180 Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 180 Life Sciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATNF or NBY?
180 Life Sciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. 180 Life Sciences's net income of -$836.7K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, 180 Life Sciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 180 Life Sciences is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATNF180 Life Sciences-- -- -- -$836.7K NBYNovaBay Pharmaceuticals0.07x -- $2.4M -$1.2M
-
Which has Higher Returns ATNF or OGEN?
Oragenics has a net margin of -- compared to 180 Life Sciences's net margin of --. 180 Life Sciences's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATNF180 Life Sciences-- -$0.85 -- OGENOragenics-- -$0.38 -- -
What do Analysts Say About ATNF or OGEN?
180 Life Sciences has a consensus price target of --, signalling upside risk potential of 96102.49%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 21851.22%. Given that 180 Life Sciences has higher upside potential than Oragenics, analysts believe 180 Life Sciences is more attractive than Oragenics.
Company Buy Ratings Hold Ratings Sell Ratings ATNF180 Life Sciences0 0 0 OGENOragenics0 0 0 -
Is ATNF or OGEN More Risky?
180 Life Sciences has a beta of 0.139, which suggesting that the stock is 86.106% less volatile than S&P 500. In comparison Oragenics has a beta of 0.403, suggesting its less volatile than the S&P 500 by 59.712%.
-
Which is a Better Dividend Stock ATNF or OGEN?
180 Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 180 Life Sciences pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATNF or OGEN?
180 Life Sciences quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. 180 Life Sciences's net income of -$836.7K is higher than Oragenics's net income of -$2.5M. Notably, 180 Life Sciences's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 180 Life Sciences is -- versus 1.61x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATNF180 Life Sciences-- -- -- -$836.7K OGENOragenics1.61x -- -- -$2.5M
-
Which has Higher Returns ATNF or PTN?
Palatin Technologies has a net margin of -- compared to 180 Life Sciences's net margin of -2357.27%. 180 Life Sciences's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATNF180 Life Sciences-- -$0.85 -- PTNPalatin Technologies-- -$0.39 -$111.5K -
What do Analysts Say About ATNF or PTN?
180 Life Sciences has a consensus price target of --, signalling upside risk potential of 96102.49%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1187.88%. Given that 180 Life Sciences has higher upside potential than Palatin Technologies, analysts believe 180 Life Sciences is more attractive than Palatin Technologies.
Company Buy Ratings Hold Ratings Sell Ratings ATNF180 Life Sciences0 0 0 PTNPalatin Technologies0 0 0 -
Is ATNF or PTN More Risky?
180 Life Sciences has a beta of 0.139, which suggesting that the stock is 86.106% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.
-
Which is a Better Dividend Stock ATNF or PTN?
180 Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 180 Life Sciences pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATNF or PTN?
180 Life Sciences quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. 180 Life Sciences's net income of -$836.7K is higher than Palatin Technologies's net income of -$7.8M. Notably, 180 Life Sciences's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 180 Life Sciences is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATNF180 Life Sciences-- -- -- -$836.7K PTNPalatin Technologies-- -- $350K -$7.8M
-
Which has Higher Returns ATNF or TOVX?
Theriva Biologics has a net margin of -- compared to 180 Life Sciences's net margin of --. 180 Life Sciences's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATNF180 Life Sciences-- -$0.85 -- TOVXTheriva Biologics-- -$6.81 -- -
What do Analysts Say About ATNF or TOVX?
180 Life Sciences has a consensus price target of --, signalling upside risk potential of 96102.49%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 5131.21%. Given that 180 Life Sciences has higher upside potential than Theriva Biologics, analysts believe 180 Life Sciences is more attractive than Theriva Biologics.
Company Buy Ratings Hold Ratings Sell Ratings ATNF180 Life Sciences0 0 0 TOVXTheriva Biologics0 0 0 -
Is ATNF or TOVX More Risky?
180 Life Sciences has a beta of 0.139, which suggesting that the stock is 86.106% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.
-
Which is a Better Dividend Stock ATNF or TOVX?
180 Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 180 Life Sciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATNF or TOVX?
180 Life Sciences quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. 180 Life Sciences's net income of -$836.7K is higher than Theriva Biologics's net income of -$7.7M. Notably, 180 Life Sciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 180 Life Sciences is -- versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATNF180 Life Sciences-- -- -- -$836.7K TOVXTheriva Biologics1.59x -- -- -$7.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 30.64% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is up 22.41% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is up 18.99% over the past day.
